
News
Stay up to date. The MLL Munich Leukemia Laboratory stands for innovation and the best leukemia diagnostics. Here you will find the latest research and study results related to hematological diagnostics and the therapy based on them, as well as other exciting news and events.
The magazine
Sven Maschek
at 17.04.2023
Rethinking diagnostics and research: Our AI team introduces itself
Every day, the MLL team works together to provide the best therapy for patients worldwide through rapid and targeted leukemia diagnostics. The use of artificial intelligence and digital processes is playing an increasingly central role in this. Our magazine series "The MLL introduces itself" gives you an insight into our laboratory, in this part we would like to introduce you to our Team AI.
Dr. rer. nat. Sabine Riedel
at 14.02.2023
MLL Introduces Itself: Our Knowledge Management
Since our founding, MLL has been generating a wide range of knowledge on a daily basis to advance leukemia diagnostics and therapy for the benefit of patients. In order to bring this knowledge together in a central location, to structure it and to make it available to employees and colleagues who send in information in a comprehensible and up-to-date manner, the Knowledge Management department was created. We have summarized the most important information about this new department for you.
Prof. Dr. med. Claudia Haferlach
at 06.02.2023
New: The Hematology Genome Network Introduces Itself
The Genome Network Hematology was founded with the aim of better networking state-of-the-art diagnostics and targeted therapy and establishing knowledge-generating patient care. Data from research projects and patient care are brought together here. Findings from patient care drive new research projects, the results of which in turn improve patient care. For example, the Hematology Genome Network aims to advance personalized medicine in hematology. We have summarized further information for you.
Sarah Gallinger
at 01.02.2023
MLL Munich Leukemia Laboratory Receives the TOP 100 Seal Again
MLL Munich Leukemia Laboratory was once again able to score points with its innovative spirit to receive the TOP 100 seal for the fifth time in a row. This award, which is presented as part of the TOP 100 Innovation Competition, is only given to especially innovative medium-sized companies. On June 23, 2023, Ranga Yogeshwar, science journalist and mentor of the competition, will personally congratulate MLL on its success at the German SME Summit in Augsburg.
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 20.12.2022
We want to say thank you: The MLL Annual Review for 2022
The year 2022 was of particular importance for us as MLL. Many diagnostic innovations and guidelines for diagnostics, classification and prognosis are changing our laboratory workflow in many places - first and foremost the newly published WHO classification (5th Edition). The latest technology and artificial intelligence are also increasingly entering the routine. In this article, the MLL management looks back on an exciting year, highlights special highlights and thanks all our senders, partners and employees.
Dr. rer. nat. Christine Käppel
at 12.10.2022
MLL Introduces Itself: Our Quality Management
Every day, the MLL team works together to provide the best therapy for patients worldwide through rapid and targeted leukemia diagnostics. But what exactly does the day-to-day work of the more than 250 employees look like? Which departments and areas are there? Our magazine series "The MLL introduces itself" gives you an insight into our laboratory. In this part, we would like to introduce you to our Quality Management (QM) department.
Prof. Dr. med. Wolfgang Kern
at 18.04.2023
Diagnostic potential of immunophenotypic aberrations in MDS
A reliable diagnosis of myelodysplastic neoplasms (MDS) requires a comprehensive and integrated diagnostic approach. A recent study shows that immunophenotyping is of great importance in this regard and can be performed using 17 different immunophenotypic parameters. In particular, the percentage of myeloid progenitor cells (MPC) was identified as a strong indicator for MDS. Read our article to learn more about the importance of immunophenotyping in the diagnosis of MDS.
PD Dr. med. Gregor Hörmann, PhD
at 17.04.2023
Update: the Onkopedia recommendations on chronic lymphocytic leukemia (CLL)
Teaser: The Onkopedia recommendations on chronic lymphocytic leukemia (CLL) have been updated. In addition to adjustments to the current WHO classification, chemotherapy-free treatment regimens are now the focus for all lines of therapy. Molecular and cytogenetic testing (deletion 17p, TP53 mutation, IGHV status, and complex karyotype) remain essential for therapy selection in both first-line and relapsed settings. In addition, specific resistance mutations after therapy with BTK or BCL2 inhibitors can be investigated by molecular genetics.
Dr. rer. nat. Frank Dicker
at 17.04.2023
BAX mutations mediate venetoclax resistance in AML
The use of targeted therapies in the treatment of leukemias has become increasingly important in recent years. However, due to the genetic instability of tumor cells, resistance to the corresponding therapeutics often develops. Identification of the resistance mechanisms is of great importance in order to use alternative treatment regimens and options if necessary. In this article, we present the latest mechanisms leading to resistance formation in AML following treatment with venetoclax. Here, acquired mutations in the BAX gene play the crucial role.
Dr. Dr. med. Armin Piehler, PhD MM
at 15.02.2023
Hemoglobinopathies – Thalassemia and Abnormal Hemoglobins
MLL is expanding its range of examinations to include complete diagnostics for the identification and characterization of hemoglobinopathies. These include thalassemias as relevant differential diagnoses to iron deficiency or abnormal hemoglobins, e.g. HbS in sickle cell disease. The combination of high-resolution hemoglobin differentiation by capillary electrophoresis and comprehensive modern molecular genetics allows rapid and unequivocal diagnosis. Thus, MLL contributes to the management of these diseases, which are increasingly observed in hematological practice.
Dr. rer. nat. Manja Meggendorfer, MBA
at 20.12.2022
Transcriptome Analysis with B-ALL and MLN-TK
Fusion transcripts and expression profiling are keywords that are important in the diagnosis of both B-ALL and MLN-TK. In the new WHO classification, the benefit but also the need of transcriptome analysis becomes clear for both entities. In both diagnostic approaches we use whole-transcriptome-sequencing and in B-ALL we use machine learning trained algorithms for classification based on expression profiles.
Dr. med. Christian Pohlkamp
at 20.12.2022
WHO, ELN and IPSS-M: Adjusting Our Diagnostic Service
New diagnostic and prognostic recommendations (WHO, ELN, IPSS-M) place increased demands on the clinically active hematologist, but also increase the information content of diagnostic data. Of course, we have adapted our diagnostic offer and especially our molecular genetic standard panels accordingly. In addition, in order to support our submitting colleagues in the interpretation of findings, we have also taken into account the latest changes in diagnostic recommendations in our "Integrated Findings". You can read everything else in the article.
Dr. rer. nat. Isolde Summerer
at 06.10.2022
Chromosome Analysis 5.0 – Automation, Digitization and Artificial Intelligence
Chromosome analysis is an essential part of the diagnostics of malignant hematological diseases. It plays an important role in confirming the diagnostics, classification, prognosis assessment and therapy planning. The method is considered time-consuming and demanding, both laboratory-wise and in terms of evaluation and reporting. In addition to the continuous expansion of the automation of laboratory processes, the use of artificial intelligence (AI) in chromosome analysis in particular enables a significant reduction in the reporting time as well as a more objective and sensitive assessment of chromosomal changes.
Dr. rer. nat. Constanze Kühn
at 16.08.2021
MTLAs, doctors and artificial intelligence at MLL – a good team!
Dr. med. Christian Pohlkamp
at 06.08.2021
MLL and Institute of AI for Health of the Helmholtz Center of Munich Announce Research Collaboration
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 30.09.2020
BELUGA - A Prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology
Dr. rer. nat. Ines Schmidts
at 18.02.2020
The Use of Artificial Intelligence at MLL Munich Leukemia Laboratory
Niroshan Nadarajah
at 18.11.2019
MLLi:ir - A diagnostic interpretation report for NGS data
Dr. Wencke Walter
at 09.01.2023
Research Report 2022
Those who know us know that we always look ahead, push boundaries, and rarely stand still. We have reviewed the last scientific year and summarized our research highlights in the new Research Report 2022. Feel free to get caught up in our own passion and immerse yourself in our research with us. In 2022, we were once again energized, curious, and enthusiastic about advancing the best possible leukemia diagnostics for our patients. To further facilitate reading and to better convey our data, we have included various graphical representations and summaries and we hope you enjoy the content.
Dr. Wencke Walter
at 15.03.2022
Leukaemia diagnosis – Realising the potential of whole transcriptome sequencing
In AML and ALL the application of WHO classification and ELN guidelines requires a plethora of methods to determine the diagnostic and prognostic subgroup. Especially in ALL, many different subtypes have been described, which makes accurate diagnosis a challenge. However, in recent years, whole genome and whole transcriptome sequencing have emerged as comprehensive high-throughput techniques that allow for an accurate genetic characterization. This identification of patients’ genetic fingerprint is key to a precise diagnosis and the design of personalised cancer treatments.
Dr. Wencke Walter
at 28.12.2021
Research Report 2021
Dr. Wencke Walter
at 10.02.2020
Genomic & Transcriptomic Data Visualization
Dr. Wencke Walter
at 04.12.2019
Analysis of pharmacogenomic variants by WGS data for AML patients with altered response to treatment
Dr. Wencke Walter
at 02.12.2019
AML and MDS – the ever-expanding potential of genetics to define clinically relevant subclasses
21.10.2023
Mikroskopierkurse MADE
Das Würmtal-Labor und das MLL Münchner Leukämielabor veranstalten gemeinsam - und erstmals in Kooperation - die Mikroskopierkurs-Reihe MADE (Mikroskopieren, Analysieren, Diskutieren, Einpacken). Insgesamt bieten wir 3 Kurse (MADE By Yourself, MADE für die Zukunft, MADE @ home) zu unterschiedlichen Zeitpunkten an. Für alle Infos zum Programm sowie zur Anmeldung hier klicken.
19.07.2023
Fortbildungsveranstaltung Teil 3
Das MLL setzt die Fortbildungsreihe mit der nächsten Veranstaltung "Hämatologische Erkrankungen mit Keimbahn-Prädisposition - Einzelfälle oder häufiger als gedacht?" fort und lädt am 19. Juli von 16 Uhr bis 18 Uhr virtuell ein. Hier finden Sie alle weiteren Informationen.
04.07.2023
European Hamilton Innovation Days 2023
Between July 4th and 6th, 2023, the European Hamilton Innovation Days 2023 will take place at the MLL Munich Leukemia Laboratory. Here you will have the opportunity to gain exclusive insights into the latest developments and innovations in automation industriy. Get to know different robots and automation software from Hamilton and exchange ideas with experts live on site. We look forward to your registration, all information can be found here.
22.06.2023
Fortbildung: Vom Myelom zum MDS
Das MLL hat zusammen mit dem Comprehensive Cancer Center Klinikum Rechts der Isar TUM und dem Comprehensive Cancer Center Mainfranken/Universitätsklinikum Würzburg das Genomnetzwerk Hämatologie gegründet. Jetzt veranstaltet das Genomnet seine erste Fortbildungsveranstaltung "Vom Myelom zum MDS" und lädt am 22. Juni von 16 Uhr bis 18 Uhr ins MLL Münchner Leukämielabor ein. Auch eine virtuelle Teilnahme ist möglich. Hier finden Sie alle weiteren Informationen.
16.11.2022
Fortbildungsveranstaltung Teil 2: WHO, ICC, ELN/AML und IPSS-M
Unsere Fortbildungsveranstaltung mit dem Thema "WHO, ICC, ELN/AML und IPSS-M: Die Bedeutung der Genetik für myeloische Entitäten von CCUS bis AML" ging am 16.11.2022 von 16.00 bis 18.00 Uhr in die zweite Runde: Im Fokus standen die Vielzahl an Neuerungen in den diagnostischen Guidelines. Die Veranstaltung fand virtuell statt, hier finden Sie alle Infos zum Programm sowie die Inhalte zur Nachschulung.
You may also be interested in
Your contact person

»Transparent communication both internally and externally is important to us.«
Sarah Gallinger